<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03595891</url>
  </required_header>
  <id_info>
    <org_study_id>CV185-640</org_study_id>
    <nct_id>NCT03595891</nct_id>
  </id_info>
  <brief_title>The Study of How Long Participants Stay in the Hospital After Receiving Apixaban for a Blood Clot in the Lung</brief_title>
  <official_title>Apixaban Length-Of-Stay Pulmonary Embolism Study - Hospital Admissions (ALPHA-PE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study based on a chart review of participants that presented with a sudden blood clot in
      the lung
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 20, 2017</start_date>
  <completion_date type="Anticipated">December 28, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 28, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Compare the average length of stay in secondary care</measure>
    <time_frame>60 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total length of stay, including repeat admissions</measure>
    <time_frame>During the first 30 days after presentation of PE</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of clinical characteristics of patients admitted with a PE</measure>
    <time_frame>Baseline</time_frame>
    <description>Clinical characteristics will be summarized using descriptive statistics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of demographic data of patients admitted with a PE</measure>
    <time_frame>Baseline</time_frame>
    <description>Demographic data will be summarized using descriptive statistics</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">660</enrollment>
  <condition>Pulmonary Embolism (PE)</condition>
  <condition>Pulmonary Thromboembolism</condition>
  <arm_group>
    <arm_group_label>Adult with acute PE before the introduction of apixaban</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Adult with acute PE after the introduction of apixaban</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non-Interventional</intervention_name>
    <description>Non-Interventional</description>
    <arm_group_label>Adult with acute PE after the introduction of apixaban</arm_group_label>
    <arm_group_label>Adult with acute PE before the introduction of apixaban</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients (â‰¥ 18 years of age) at index date presenting with acute Pulmonary Embolism
        (PE), which was then objectively confirmed, and received anticoagulation upon diagnosis of
        PE and in receipt of anticoagulation at discharge.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults participants at date of admission

          -  Primary presentation consistent with PE followed by objectively-confirmed acute PE

          -  Received anti-coagulation upon diagnosis of PE during study period and in receipt of
             anti-coagulation at discharge

        Exclusion Criteria:

          -  PE diagnosed during a hospital admission for a reason other than PE during the study
             period

          -  Patients receiving anticoagulation at the time of presentation

          -  Patients presenting outside the defined study period

        Other protocol defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cardiff</city>
        <zip>CF23 8RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bms.com/researchers-and-partners/investigator-inquiry-form.html</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>May 8, 2018</study_first_submitted>
  <study_first_submitted_qc>July 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2018</study_first_posted>
  <last_update_submitted>December 5, 2018</last_update_submitted>
  <last_update_submitted_qc>December 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Embolism</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

